Contains Nonbinding Recommendations

Draft Guidance on Niraparib Tosylate

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Niraparib tosylate

Dosage Form; Route: Capsule; oral

Recommended Studies: One study

Type of study: Pharmacokinetic endpoint, steady-state

Design: Multiple-dose, two-way crossover

Strength: Eq. 100 mg (base) capsule (dose = 3x100 mg=300 mg daily with or without food)

Subjects: The study should be conducted in female patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Additional Comments:

1. Attainment of steady state should be confirmed with at least 3 consecutive trough levels.
2. Blood sampling for bioequivalence should consist of appropriate sampling times over a 24-hr. period following attainment of steady state.
3. Females should not be pregnant or lactating.
4. Women of child bearing potential should be advised to use an effective method of contraception while using Niraparib and for up to 8 weeks after ending the treatment.
5. Investigators should refer to Warnings, Precautions, Contraindications and Adverse Reactions in the FDA-approved labeling and follow the recommendations closely.
6. The study should be designed around each patient's existing Niraparib regimen and no changes in dose or regimen should be made for the bioequivalence study.
7. Considering that this is a cytotoxic drug, a Bio-IND would be needed for this drug product.[1]

Analytes to measure (in appropriate biological fluid): Niraparib in plasma

[1] The Bio-IND should be filed as per the requirements outlined in 21 CFR Section 320.31

Bioequivalence based on (90% CI): Niraparib

Waiver request of in-vivo testing: N/A

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).